retatrutide triple agonist gip glp-1 glucagon phase 3 2025 🚨 Today, retatrutide, the GIP/GLP-1/glucagon agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent obesity and type 2 diabetes. 📊 Mean body weight change at 80 weeks: ⬇️ retatrutide phase 3 2025 triple

In clinical trials, GLP-1 RAs were shown to significantly lower blood pressure (BP) in addition to HbA1c and body weight (BW), indicating the possibility as anti-hypertensive medication of type 2 DM individuals

Nickander KK, McPhee BR, Low PA, Tritschler H

Lett Appl Microbiol

Parasites et maladies : reprer sans paniquer (mais agir quand mme) On croit toujours que "a narrive quaux autres" jusquau jour o on voit un ide avec des taches bizarres ou qui nage comme sil avait bu la tasse

Diabetes 52 , 26152622 (2003)

Emphasizing the crucial principle that healthy habits start early, as we delve into the importance of early adoption for optimal well-being and long-term health